- Home
- FE vs GLSI Comparison
FE vs GLSI Comparison
Compare FE & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FE | GLSI |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4B | 123.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FE | GLSI |
|---|---|---|
| Price | $49.87 | $26.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | $48.50 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 5.3M | 639.1K |
| Earning Date | 02-17-2026 | 11-14-2025 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 48.81 | N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | ★ $14,283,000,000.00 | N/A |
| Revenue This Year | $10.07 | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | $21.17 | ★ N/A |
| Revenue Growth | ★ 7.74 | N/A |
| 52 Week Low | $37.58 | $7.78 |
| 52 Week High | $49.23 | $34.10 |
Technical Indicators
Market Signals| Indicator | FE | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 72.25 | 50.41 |
| Support Level | $46.10 | $25.68 |
| Resistance Level | $49.23 | $30.13 |
| Average True Range (ATR) | 0.83 | 3.14 |
| MACD | 0.15 | -0.80 |
| Stochastic Oscillator | 94.09 | 20.84 |
Price Performance
Historical ComparisonAbout FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with operations across five mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.